KMG Fiduciary Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

KMG Fiduciary Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-531	Closed	-$208K	–	299
2025 Q3	$208K	Hold	531	–	–	0.01%	293
2025 Q2	$236K	Buy	531 +20	+4%	+$9.22K	0.02%	272
2025 Q1	$248K	Buy	+511	New	+$238K	0.02%	262
2024 Q4	–	Sell	-543	Closed	-$253K	–	281
2024 Q3	$253K	Hold	543	–	–	0.02%	248
2024 Q2	$255K	Hold	543	–	–	0.03%	219
2024 Q1	$227K	Buy	543 +50	+10%	+$21.1K	0.02%	226
2023 Q4	$201K	Buy	+493	New	+$182K	0.02%	233

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KMG Fiduciary Partners's VRTX Position: Q4 2025 in Review

KMG Fiduciary Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 531 shares — an estimated $208K sold.

KMG Fiduciary Partners first reported a position in VRTX in Q4 2023 and held it in 7 quarters. The position peaked at $255K in Q2 2024. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

KMG Fiduciary Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
KMG Fiduciary Partners sold 531 Vertex Pharmaceuticals shares in Q4 2025, an estimated $208K.
KMG Fiduciary Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 7 quarters.
KMG Fiduciary Partners's Vertex Pharmaceuticals position peaked at $255K in Q2 2024.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on KMG Fiduciary Partners's 13F filing for Q4 2025, filed 14 Jan 2026.